Category: US Health

Source: US Department of Health and Human Services – 3

Component Name
Cardinal Health Part Number
Aligned Medical Solutions Part Number
Component Lot Number

Webcol Large Alcohol Prep Pad
5110
69124
25K006462

Full List of Affected Products
What to Do
Apply the Aligned Medical Solutions over-label (see Recall Notice image below) to affected inventory. When the affected convenience kits are opened for use, remove, discard and do not use the Cardinal Health Webcol Alcohol Prep Pads.
On May 21, 2026, Aligned Medical Solutions sent all affected customers a letter recommending the following actions:

Identify affected products.
Apply the provided over-labels according to the instructions provided.
When affected kits are opened for use, remove any Cardinal Health Alcohol Prep Pads.
Mark on the removed pads that they are to be disposed of and set them aside for disposal. 
Dispose of the recalled pads following medical waste policies at your institution.
Request replacement product as needed.

Check this web page for updates. The FDA is currently reviewing information about this potentially high-risk device issue and will keep the public informed as significant new information becomes available.
Reason for Alert
Windstone Medical Packaging initiated an Urgent Medical Device Recall notice for convenience kits that contain Cardinal Health alcohol pads affected by a Cardinal Health Nationwide Recall. The Alcohol Prep Pads may be contaminated with Paenibacillus phoenicis. Use of contaminated pads for skin preparation before injections or blood draws poses risk of infection to vulnerable groups such as critically ill, immunocompromised, neonatal, and pediatric patients.
As of June 4, 2026, Windstone Medical Packaging has reported no serious injuries or deaths associated with this issue.
Device Use
The convenience kits contain various surgical instruments, dressings and/or other materials, and pharmaceutical components that are intended to be used during various surgical procedures.
Contact Information
Customers in the U.S. with adverse reactions, quality problems, or questions about this issue should contact Windstone Medical Packaging, Inc. at jjensen@alignedmedical.com or call (407) 638-9924.
Additional FDA Resources

Unique Device Identifier (UDI)
The unique device identifier (UDI) helps identify individual medical devices sold in the United States from manufacturing through distribution to patient use. The UDI allows for more accurate reporting, reviewing, and analyzing of adverse event reports so that devices can be identified, and problems potentially corrected more quickly.

How do I report a problem?  
Health care professionals and consumers may report adverse reactions or quality problems they experienced using these devices to MedWatch: The FDA Safety Information and Adverse Event Reporting Program.

Source: US Department of Health and Human Services – 3

Summary

Company Announcement Date:
June 15, 2026
FDA Publish Date:
June 16, 2026
Product Type:
Food & BeveragesAllergens
Reason for Announcement:

Recall Reason Description
Undeclared Peanuts

Company Name:
Western Mixers Produce and Nuts
Brand Name:

Brand Name(s)
First Street

Product Description:

Product Description
First Street Dark Chocolate Raisins – 9 oz (255g)

Company Announcement
Western Mixers Produce & Nuts, Inc., Ontario, California is recalling:
First Street brand, Dark Chocolate Raisins, 9 oz.,
Because the product may contain undeclared dark chocolate peanuts. People who have an allergy or severe sensitivity to peanuts run the risk of serious or life-threatening allergic reaction if they consume these products.
Lot Code Can be found on side of container: LOT# 260562
Product was distributed to Cedraui, USA and was sold at Smart & Final Stores in California.
The recalled product is as follows:
First Street brand Dark Chocolate Raisins, 9 oz., with UPC 7-97565-01183-0, packed in a clear plastic container with Lot#260562, which can be found on the side of the container.
No illnesses have been reported to date.
As a precaution we are recalling all supplies of the food with the above identification. Consumers with an allergy to peanuts should not consume the product. Consumers should return the product to the place of purchase for a full refund.
Customers with questions may contact:Western Mixers Produce & Nuts, Inc.Food Safety Department323-443-2567

Company Contact Information

Consumers:
Western Mixers Produce & Nuts, Inc. Food Safety Department
323-443-2567

Product Photos

Content current as of:
06/16/2026

Regulated Product(s)

Topic(s)

Follow FDA

Source: US Department of Health and Human Services – 3

For Immediate Release:
June 16, 2026

The U.S. Food and Drug Administration (FDA) today approved another over-the-counter (OTC) intranasal naloxone product, Rextovy, a 4 milligram (mg) naloxone hydrochloride nasal spray for the emergency treatment of opioid overdose. Consumers may directly purchase this product without a prescription in places such as pharmacies, convenience stores, and online. This action aligns with President Trump’s Great American Recovery Initiative, a federal effort to address the U.S.’ addiction and substance use disorder crisis and coordinate the government’s approach to prevention, treatment, and long-term recovery.  
“Reducing opioid overdose deaths is a top priority for FDA,” said Mike Davis M.D., Ph.D., Acting Director of the Center for Drug Evaluation and Research (CDER). “Today’s approval of an additional over-the-counter naloxone nasal spray helps broaden access and offers an additional option for consumers. Empowering people without medical training to take immediate action with these products has been proven to save lives.”  
Naloxone is a medication that rapidly reverses the effects of opioid overdose and is the standard treatment for opioid overdose. Rextovy is an additional life-saving medication approved by the FDA to reverse an opioid overdose to be sold directly to consumers and contains the same active ingredient as other naloxone nasal sprays. The availability of multiple approved formulations expands access and market availability, encourages competition that may reduce cost, and offers alternative sourcing options.
The number of overdose deaths has dramatically decreased since the first FDA approval of an OTC naloxone nasal spray in 2023, but drug overdose persists as a major public health issue in the U.S., primarily driven by synthetic opioids like illicit fentanyl. In the 12-month period ending in August 2023, 111,451 overdose deaths were reported; in the 12-month period ending in December 2025, 68,632 overdose deaths were reported.1
“Immediate access to naloxone nasal sprays is essential when a person is experiencing an overdose, and FDA remains committed to ensuring nonprescription options are widely available,” said Karen Murry, M.D., Director of the Office of Nonprescription Drug Products in CDER. “We are proud of the dedicated work our review divisions put into making this approval possible, and we encourage any manufacturer seeking to market a nonprescription naloxone product to contact the agency to initiate a conversation.”
When using Rextovy, some people may experience symptoms when they regain consciousness following overdose reversal, such as shaking, sweating, nausea, or feeling angry. The product is safe to use even when it is uncertain whether opioids are present in the person’s system. The product’s packaging includes pictorial directions with five clear steps, including calling 911 after giving the first dose.
The FDA granted the nonprescription approval to Amphastar Pharmaceuticals, Inc.
1 Products – Vital Statistics Rapid Release – Provisional Drug Overdose Data
Related Information

Related Information

Consumer:888-INFO-FDA

###

Boilerplate

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, radiation-emitting electronic products, and for regulating tobacco products.

Content current as of:
06/16/2026

Follow FDA

Source: US Department of Health and Human Services – 3

For Immediate Release:
June 15, 2026

On June 12, 2026, the U.S. Food and Drug Administration granted accelerated approval to Tzield  (teplizumab) for a new indication, to delay the decline of insulin production in pediatric patients ages 8 through 17 years who have been recently diagnosed with Stage 3 type 1 diabetes (T1D). This approval marks the first FDA-approved treatment for this indication and represents an important advancement for children living with type 1 diabetes and their families.
“The FDA recognizes the large unmet need in patients with type 1 diabetes,” said Acting Associate Director for Therapeutic Review of the Division of Diabetes, Lipid Disorders and Obesity, Mahtab Niyyati M.D. “Based on robust evidence of safety and effectiveness, this accelerated approval provides a chance for pediatric patients with recently diagnosed Stage 3 type 1 diabetes to alter the course of their disease.”
Tzield was previously approved to delay the onset of Stage 3 type 1 diabetes in adults and pediatric patients 1 year of age and older  with Stage 2 type 1 diabetes. The newly approved indication is for the use of Tzield to help delay the decline in insulin  production in certain pediatric patients who have recently been diagnosed with Stage 3 disease.
The FDA granted this application under the agency’s accelerated approval pathway. The approval was based on evidence from an adequate and well-controlled clinical trial that Tzield demonstrated a statistically significant effect on C-peptide, a  surrogate endpoint reasonably likely to predict a clinical benefit. A required postapproval study is ongoing to verify clinical benefit.    
Healthcare professionals and patients should review the prescribing information for important safety information. The approved labeling includes a boxed warning regarding serious and life-threatening cases of viral reactivation, including Epstein-Barr virus (EBV) and cytomegalovirus (CMV) reactivation, reported with Tzield. The most common side effects of the drug are vomiting, rash, increased liver transaminase (a blood test that detects liver stress or damage) and headache. Tzield is associated with a reduction in white blood cells (leukopenia), including a reduction in different types of white blood cells (lymphopenia and neutropenia) that can increase the risk for certain infections. More information: FDA Approves Drug for Pediatric Stage 3 Type I Diabetes.
###

Boilerplate

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, radiation-emitting electronic products, and for regulating tobacco products.

Content current as of:
06/15/2026

Follow FDA

Source: US Department of Health and Human Services – 3

This recall involves correcting certain devices, and does not involve removing them from where they are used or sold. The FDA has identified this recall as the most serious type. This device may cause serious injury or death if you continue to use it without correction. The affected products and recommendations for what to do with the devices below have not changed.
Affected Product
The FDA is aware that Draeger, Inc. has issued a letter to affected customers recommending certain anesthesia machines be corrected prior to continued use. Affected devices:

Product Names: Atlan A350 and Atlan A350XL anesthesia workstations
Unique Device Identifier (UDI)/Model:

What to Do
Until Draeger, Inc. can replace the ventilator motor assembly use these devices with close, constant supervision.On May 7, Draeger, Inc. sent all affected customers a letter recommending the following actions:

Customers may continue using devices under permanent supervision until the ventilator motor assembly can be replaced
If the mechanical ventilation fails:

Use Manual/Spontaneous ventilation mode to ventilate the patient manually as needed.
Monitor the patient’s condition – specifically their oxygenation status as a brief cessation of ventilation can potentially lead to injury.

If preferred, downgrade the alarm priority of the “Ventilator error!!!” to “ALARM RESET” after switching to Manual/Spontaneous ventilation mode.
Make sure all users of the Draeger Atlan and others in the organization with concern for this device know about the notice.
Forward the notice to any third parties who may have received these products.

Reason for Correction
Draeger, Inc., is expanding their October 2024 correction to include additional Atlan A350 and A350 XL anesthesia workstations. This correction is due to a manufacturing error that may cause the piston ventilator to fail before use or mechanical ventilation to fail during use.
If the error occurs before use, such as in standby or system test mode, mechanical ventilation cannot be started. If the error occurs during a procedure, the mechanical ventilation may fail, and the device alerts the user by displaying the “Ventilator error!!!” message. Manual ventilation or spontaneous breathing remains possible in both cases. It may be necessary to manually ventilate the patient to prevent injury. With the ongoing alarm of the ventilation failure, the Atlan continues to provide the Manual/Spontaneous ventilation mode, fresh-gas and agent delivery as well as all monitoring functions without restriction.
Draeger will replace the ventilator motor assembly on affected devices. Customers will be contacted by their local Draeger Service Representative to arrange a date for the ventilator motor assembly replacement.
The use of affected product may cause serious adverse health consequences, including lack of oxygen (hypoxia), loss of the ability to expand the lungs (lung recruitment), slow heart rate (bradycardia), sudden heart stop (cardiac arrest), and death.As of May 6, 2026, there have been no reported injuries and no reports of death.  
Device Use
The Atlan A350 and A350 XL anesthesia workstations are intended for use in anesthetizing adults, children, and neonates and can be used for automatic and manual ventilation, pressure-supported spontaneous breathing, and spontaneous breathing. It is used for inhaled anesthesia during surgical or diagnostic procedures.
Contact Information
Customers in the U.S. with adverse reactions, quality problems, or questions about this issue should contact Draeger Service Technical Support at 1-800-437-2437.
Additional FDA Resources

Anesthesia Machine Correction: Draeger, Inc., Issues Correction for Atlan A350 and A350 XL Anesthesia Workstations Due to Possible Mechanical Ventilation Failure | FDA [11/19/2024]  
FDA Enforcement Report – 11/2024 recall
CDRH Medical Device Recalls Database – 11/2024 recall
FDA Enforcement Report
CDRH Medical Device Recall Database

Unique Device Identifier (UDI)
The unique device identifier (UDI) helps identify individual medical devices sold in the United States from distribution to use. The UDI allows for more accurate reporting, reviewing, and analyzing of adverse event reports so that devices can be identified more quickly, and as a result, problems potentially resolved more quickly.

How do I report a problem?
Health care professionals and consumers may report adverse reactions or quality problems they experienced using these devices to MedWatch: The FDA Safety Information and Adverse Event Reporting Program.
Timeline of Communication Updates

Date
Actions

06/15/2026
The FDA updated this communication to inform the public that this issue has been classified as a Class I Recall.

05/15/2026
The FDA issued an Early Alert communication to notify the public of a potentially high-risk device issue. 

Content current as of:
06/15/2026

Regulated Product(s)

Source: US Department of Health and Human Services – 3

Summary

Company Announcement Date:
June 13, 2026
FDA Publish Date:
June 13, 2026
Product Type:
Food & Beverages
Reason for Announcement:

Recall Reason Description
Potential risk of Clostridium botulinum contamination.

Company Name:
Nara Organics
Brand Name:

Brand Name(s)
Nara Organics

Product Description:

Product Description
Whole Milk Powdered Infant Formula

Company Announcement
Nara Organics of New York, NY, is voluntarily recalling all lots of Nara Organics Powdered Infant Formula currently on the market out of an abundance of caution due to the potential risk of Clostridium botulinum contamination.
Infant botulism is a rare but potentially fatal illness that presents a serious threat to the health of infants which occurs when Clostridium botulinum spores are ingested and colonize the intestinal tract, producing botulinum neurotoxins in the immature gut of infants. Affected infants can present with some or all of the following signs and symptoms: constipation, poor feeding, ptosis (drooping eyelid), sluggish pupils, low muscle tone, difficulty sucking and swallowing, weak or altered cry, generalized weakness, respiratory difficulty, and possibly respiratory arrest.
Nara Organics Powdered Infant Formula was distributed nationally across Target retail stores, Target.com, and Nara.com between July 2025 and June 2026. Nara Infant Formula is not distributed outside of the USA.
Affected Product Details:

Nara Organics Whole Milk Infant Formula, 700g, with UPC 860013251901
Nara Organics Whole Milk Infant Formula, 400g, with UPC: 860013251918

All lots currently on the market are included in this voluntary recall, and the specific codes are as follows. The lot code can be found on the bottom of each can.

408125075E14F2
708125076E14F2
708125083E14F2
408125139E14F2
708125141E14F2
708125145E14F2
708125174E14F2
709125273E14F2
709125280E14F2
709125288E14F2
409125307E14F2
70926019ENNB
70926029ENNB
70926035ENNB
70926039ENNB
70926042ENNB

The Food and Drug Administration (FDA) and Center for Disease Control (CDC) contacted Nara Organics late Friday, June 12, 2026, and provided information about 3 cases of infant botulism in infants who CDC reported had consumed Nara formula. The 3 infants were hospitalized and treated with BabyBIG (Botulism Immune Globulin Intravenous) in California, Washington, and Pennsylvania. There are no reported deaths. The three specific product lots these infants were exposed to are: 709125280E14F2, 709125288E14F2, 708125174E14F2. To date, Nara infant formula has not tested positive for C. botulinum. However, Nara is voluntarily recalling all products currently in market.
Nara is taking aggressive action to ensure the safety of the babies and families who use the product as we work closely with the FDA, Centers for Disease Control and Prevention (CDC), and state partners to support their investigation into the root causes of these cases.
Customers should stop using the affected products immediately. If your baby has consumed this product and is presenting symptoms of infant botulism including, but not limited to vomiting, diarrhea, constipation, poor feeding, drooping eyelids, and weak crying, please contact your healthcare provider for immediate care.
To report an illness or adverse event, you can:

Nara will automatically refund all consumers who purchased formula from their website in May and June 2026. Other customers with unused product may request a refund by taking a photo of the bottom of each can and completing the refund form here:
https://nara.com/pages/refund-request-form. Target customers may return their product to Target retail locations or follow Target’s online return instructions.
We sincerely apologize for the concern and distress this announcement causes our customers. We are committed to leading with transparency and accountability throughout this process as we work to identify further information. We will provide additional information as it becomes available. Customers with questions are encouraged to visit Nara’s website or email hello@nara.com.
FDA Outbreak Advisory

Company Contact Information

Product Photos

Source: US Department of Health and Human Services – 3

For Immediate Release:
June 12, 2026

The U.S. Food and Drug Administration today cleared for marketing the first over-the-counter (OTC) continuous glucose monitor (CGM) for children, Dexcom Inc.’s Stelo Glucose Biosensor System, an integrated CGM (iCGM) indicated for people two years of age and older who do not use insulin. The FDA previously cleared the Stelo Glucose Biosensor System OTC for individuals 18 years and older in March 2024.
“Children deserve access to the best tools available to manage their health,” said Center for Devices and Radiological Health Director Michelle Tarver, M.D., Ph.D. “Today’s clearance reflects the FDA’s commitment to fostering innovation for pediatric patients and supporting the safe and effective use of medical devices where children live, learn, and play.”
Prediabetes is increasingly impacting children in the United States, placing millions at heightened risk for progressing to Type 2 diabetes. OTC CGMs can play a critical role in addressing this public health concern for pediatric users who do not use insulin. By providing real-time glucose data, these devices can help pediatric patients and their caregivers build greater glycemic awareness, track patterns in response to meals and exercise, and make informed adjustments to support healthier long-term outcomes and quality of life.
The product is indicated for children, including those with diabetes, who receive oral medication to manage their condition and people who want to understand how diet, exercise, and other lifestyle changes affect their glucose levels.
The Stelo Glucose Biosensor System uses a wearable sensor, paired with an application installed on a compatible smartphone, or other smart device, such as a parent’s or caregiver’s smartphone, to continuously measure, record, analyze and display glucose values. Each sensor lasts for up to 15 days before it must be replaced, although sensor wear time may be shorter in pediatric users than in adults due to several interconnected physiological and behavioral factors. The app displays glucose measurements and trends every 15 minutes. Users and their caregivers should consult their health care provider before making any medication adjustments based on the device’s output.
This clearance is an example of the FDA’s use of real-world evidence (RWE) to support regulatory decision-making. Dexcom and the FDA used previous clinical study data from both pediatrics and adults, along with RWE derived from real-world data on current iCGM use among both groups, to understand expected device performance in pediatric users over the full 15-day wear period.
Participants in the previous study reported mild adverse events including local infection, skin irritation, and pain or discomfort.
For children, the device should be used under the supervision of an adult caregiver. Importantly, this system is not for people with problematic hypoglycemia (low blood sugar) because it is not designed to alert users when this potentially dangerous condition occurs. This system is also not for people on dialysis. People with a history of disordered eating or eating disorders should talk with their health care provider before using Stelo.
This clearance is also aligned with the FDA’s Home as a Health Care Hub Initiative, which focuses on advancing the development of innovative, patient-centered devices that fit more seamlessly into people’s daily lives at home.

Consumer:888-INFO-FDA

###

Boilerplate

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, radiation-emitting electronic products, and for regulating tobacco products.

Content current as of:
06/12/2026

Follow FDA

Source: US Department of Health and Human Services – 3

This recall involves correcting certain devices and does not involve removing them from where they are used or sold. The FDA has identified this recall as the most serious type. This device may cause serious injury or death if you continue to use it without correction.  
Affected Product
The FDA is aware that Medline has issued a letter to affected customers recommending certain convenience kits be corrected prior to continued use by removing included Bupivacaine Hydrochloride in Dextrose Injections.
Affected devices:

What to Do
Do not use Bupivacaine Hydrochloride included in affected kits. Check your stock for convenience kits containing Bupivacaine Hydrochloride in Dextrose Injections and quarantine until over-labels are provided. All remaining components within the kits may continue to be used.
On April 10, Medline sent all affected customers a letter recommending the following actions:

Immediately check your stock for the affected item and lot numbers. Quarantine all affected product.
Complete the recall response form to receive over-labels to place on affected inventory.
Place over-labels on the affected product. The labels provide instructions for staff to remove and discard the affected component prior to using the kit.
If you have distributed, resold, or transferred affected products to other companies or individuals, notify them of this recall.

Reason for Correction
Medline Industries is removing Huons Bupivacaine Hydrochloride in Dextrose Injection, USP from certain convenience kits. Huons Co., Ltd. initiated a recall of Bupivacaine HCL in Dextrose Injection, USP following a recent FDA inspection of its manufacturing facility, which identified quality issues. Risks of using compromised injectables include infection, inflammatory response and/or reduced anesthetic effectiveness. When used in the neuraxial space, there is a risk of cerebral fluid contamination and meningitis that may progress to encephalitis.
As of April 10, Medline has reported no serious injuries and deaths associated with this issue.
Device Use
Convenience kits contain various surgical instruments, dressings and/or other materials, and pharmaceutical components that are intended to be used during various surgical procedures.
Contact Information
Customers in the U.S. with questions about this recall should contact Medline Industries at 1-866-359-1704, or via email at recalls@medline.com.
Additional FDA Resources:

Unique Device Identifier (UDI)
The unique device identifier (UDI) helps identify individual medical devices sold in the United States from manufacturing through distribution to patient use. The UDI allows for more accurate reporting, reviewing, and analyzing of adverse event reports so that devices can be identified, and problems potentially corrected more quickly.

How do I report a problem?
Health care professionals and consumers may report adverse reactions or quality problems they experienced using these devices to MedWatch: The FDA Safety Information and Adverse Event Reporting Program.

Content current as of:
06/12/2026

Source: US Department of Health and Human Services – 3

Summary

Company Announcement Date:
June 11, 2026
FDA Publish Date:
June 11, 2026
Product Type:
Food & BeveragesFoodborne Illness
Reason for Announcement:

Recall Reason Description
Possible Salmonella Contamination

Company Name:
Total Nutrition Inc.
Brand Name:

Brand Name(s)
TNVitamins and Doctor’s Pride

Product Description:

Product Description
TNVitamins Ultra Potent Complete Green Superfood Capsules and Doctor’s Pride Complete Green Superfood capsules

Company Announcement
Total Nutrition Inc. of Deer Park, NY is voluntarily expanding its recall of TNVitamins and Doctor’s Pride Ultra Potent Complete Green Superfood Moringa Capsules due to the potential to be contaminated with Salmonella. This expansion follows an ongoing supply chain investigation that identified additional lot numbers linked to the same raw material lot that prompted the original recall. Salmonella is an organism which can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems. Healthy persons infected with Salmonella often experience fever, diarrhea (which may be bloody), nausea, vomiting and abdominal pain. In rare circumstances, infection with Salmonella can result in the organism getting into the bloodstream and producing more severe illnesses such as arterial infections (i.e., infected aneurysms), endocarditis, and arthritis.
The recalled product was distributed nationally through the online platforms, Amazon, Walmart, TikTok Shop, Target, and the company’s websites, http://www.tnvitamins.com/, and https://www.doctorspride.com/.
The product is packaged in white HDPE supplement bottles with smooth, white caps and 120 clear capsules filled with green moringa powder. Some of the affected lots are:

Product

Lots

TNVitamins Ultra PotentComplete Green Superfood Moringa10,000 mg (120 capsules)

Lot: 2507199 Exp. 09/2027

Lot: 2512-304 Exp. 02/2028

Lot: 2793 Exp. 02/2028

Lot: 2748 Exp 07/2027

Lot: 2725 Exp. 04/2027 (newly added)

Lot: 2503104 Exp. 04/2027 (newly added)

Doctor’s Pride Complete GreenSuperfood Ultra Potent Moringa10,000 mg (120 capsules)

The recall was initiated following notification from the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) that these products may be implicated in an ongoing investigation associated with moringa-containing dietary supplement products. Total Nutrition Inc. has ceased distribution and sale of the identified product and has initiated removal orders across all applicable sales and fulfillment channels while the FDA, CDC and the company continue their investigation.
This expansion was discovered during a supply chain traceability review which identified a common raw material from Lot 2507199 or 2512-304, one of the original recalled lots.
Total Nutrition Inc. is including Lots 2503104, and 2725 of TNVitamins Ultra Potent Complete Green Superfood Moringa 10,000 mg and Doctor’s Pride Complete Green Superfood Ultra Potent Moringa 10,000 mg in the recall effective immediately.
No other TNVitamins or Doctor’s Pride products are involved.
Customers who have purchased the affected products are asked to dispose of them immediately. Do not eat, sell, or serve the product. Customers may request a refund by contacting TNVitamins at customerservice@tnvitamins.com and providing your name, order number, and a photo of the product with lot codes in question.
We apologize for the inconvenience and concern this recall may cause to our customers. TNVitamins is committed to ensuring the quality of our products and the well-being of our consumers.
Link to Expanded Press Release
Link to Original Press Release
Link to FDA Advisory

Company Contact Information

Product Photos

Content current as of:
06/11/2026

Regulated Product(s)

Topic(s)

Follow FDA